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Background: Overexpression of EGFR is a negative prognostic factor in head
and neck squamous cell carcinoma (HNSCC). Patients with HNSCC who respond
to EGFR-targeted tyrosine kinase inhibitors (TKIs) eventually develop acquired
resistance. Strategies to identify HNSCC patients likely to benefit from EGFR-targeted
therapies, together with biomarkers of treatment response, would have clinical
value.
Methods: Functional MRI and 18F-FDG PET were used to visualize and quantify imaging
biomarkers associated with drug response within size-matched EGFR TKI-resistant CAL
27 (CALR) and sensitive (CALS) HNSCC xenografts in vivo, and pathological correlates
sought.
Results: Intrinsic susceptibility, oxygen-enhanced and dynamic contrast-enhanced
MRI revealed significantly slower baseline R2
∗, lower hyperoxia-induced 1R2
∗ and
volume transfer constant Ktrans in the CALR tumors which were associated with
significantly lower Hoechst 33342 uptake and greater pimonidazole-adduct formation.
There was no difference in oxygen-induced 1R1 or water diffusivity between the
CALR and CALS xenografts. PET revealed significantly higher relative uptake of
18F-FDG in the CALR cohort, which was associated with significantly greater Glut-1
expression.
Conclusions: CALR xenografts established from HNSCC cells resistant to EGFR TKIs
are more hypoxic, poorly perfused and glycolytic than sensitive CALS tumors. MRI
combined with PET can be used to non-invasively assess HNSCC response/resistance
to EGFR inhibition.
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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is a
significant cause of morbidity and mortality, with almost
700,000 new cases estimated annually, worldwide (1). For locally
advanced head and neck cancer (LAHNC), the standard of care is
chemoradiotherapy (with/without initial surgery) (2). Even with
aggressive multimodality management, the majority of patients
with LAHNC develop incurable locoregional or systemic relapse
(3). For patients with recurrent and/or metastatic (R/M) disease,
prognosis is poor and survival rates are dismal, highlighting a
requirement for novel therapeutic options together with clinically
useful predictive biomarkers (4).
The epidermal growth factor receptor (EGFR) belongs to the
ErbB/HER family of transmembrane receptor tyrosine kinases
and has a key role in HNSCC (5). Ligand binding to EGFR
activates many downstream signaling pathways, promoting cell
proliferation, survival, DNA repair, migration, invasion and
angiogenesis (6). Elevated expression of EGFR occurs in >80%
HNSCC, and is associated with poor prognosis and treatment
resistance (7, 8). EGFR is thus a compelling therapeutic target,
and a number of EGFR family antagonists have been developed
(5, 6). The monoclonal antibody cetuximab has an established
role in combination with radiotherapy in newly-diagnosed
LAHNC (9), and with cisplatin/5-FU in R/M disease (10).
Clinical responses to first generation EGFR tyrosine kinase
inhibitors (TKIs), such as gefitinib or erlotinib, in HNSCC
were disappointing (11). However afatinib, an irreversible HER
family inhibitor, recently demonstrated improved progression-
free survival in patients with R/M HNSCC (12). Nevertheless,
the overwhelming majority of patients who initially respond to
targeted therapies only achieve stable disease of short duration
and acquired resistance usually manifests within 6–12 months
(13–15).
A clinical definition of acquired resistance to EGFR TKIs has
been proposed for patients with non-small cell lung cancer (16).
These guidelines are based on detecting known drug-sensitizing
EGFR mutations, combined with anatomical imaging, to detect
disease progression whilst on therapy. However, in HNSCC,
this approach is not applicable, since EGFR mutations are rare
(17). Furthermore, levels of EGFR protein do not correlate with
clinical response to EGFR TKIs in HNSCC (13, 18). Alternative
strategies to identify HNSCC patients who are likely to benefit
from EGFR-targeted therapies, together with biomarkers of
response for monitoring therapy, are urgently required (19, 20).
An additional challenge in the treatment of the often bulky
HNSCC tumors is hypoxia. The low levels of oxygen that
result from an anarchic tumor vasculature and uncontrolled
cell division are a well-established cause of treatment resistance
and adversely affect HNSCC prognosis (21, 22). Under hypoxic
conditions, altered gene transcription and adaptive signaling
networks enable cancer cells to resist apoptosis and continue
to proliferate in adversity, leading to the development of an
increasingly aggressive tumor (23, 24). Expression and activation
of EGFR are moderated by hypoxia although the mechanisms
involved are yet to be fully elucidated (25). Co-localization of
hypoxic regions and EGFR expression has been demonstrated
in HNSCC biopsies and was associated with poor outcome (26).
Conversely, hypoxic areas of HNSCC tumors were found to have
reduced EGFR expression (27), possibly due to degradation of
EGFR by the hypoxia-induced protein PHD-3 (28), and this was
proposed as a putative mechanism of resistance to anti-EGFR
therapies.
For the assessment of molecularly targeted agents such
as TKIs, the standard response evaluation criteria in solid
tumors (RECIST) may be suboptimal (29). This is particularly
pertinent in the context of drug resistance, where genomic
and morphological transformations typically precede changes
in tumor volume. Advances in imaging technologies provide
a means of defining non-invasive quantitative biomarkers to
inform on biologically relevant structure-function relationships
in tumors, enabling their accurate detection, an understanding
of their behavior, and informing on response to targeted and,
by extension, conventional treatments, at relatively early time
points (30). Predictive imaging biomarkers of sensitivity and
resistance to targeted anti-cancer treatments would thus provide
opportunities to deliver personalized and more effective therapy
regimes (31, 32).
To investigate EGFR TKI resistance in HNSCC, we have
generated a CAL 27 cell line, CALR, that is resistant to multiple
EGFR TKIs (gefitinib, erlotinib, lapatinib and afatinib) (33). An
isogenic control cell line, CALS, retained sensitivity to EGFR
TKIs in vitro and in vivo (33). The aim of this study was
to exploit CALR/S xenografts to identify clinically translatable
functional imaging biomarkers that (i) correctly report on
the pathology and processes relevant to acquired resistance
to EGFR inhibition in HNSCC in vivo and (ii) may have
value in assessing response to targeted EGFR inhibition and,
potentially, conventional radiotherapy/chemotherapy. To this
end, a range of advanced magnetic resonance imaging (MRI)
and positron emission tomography (PET) techniques, and the
quantitative imaging biomarkers they afford, were evaluated and
pathologically qualified to assess tumor hypoxia, angiogenesis
and metabolism in vivo.
MATERIALS AND METHODS
Cell Culture and Tumor Propagation
EGFR TKI-resistant CALR and -sensitive CALS HNSCC
cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum (Invitrogen, Paisley,
UK) and maintained at 37◦C in a humidified incubator
with an atmosphere of 95% air, 5% CO2 (33). Cells were
routinely screened for mycoplasma using PCR and had STR
profiles (obtained using a GenePrint R© 10 kit, Promega,
Southampton, UK and a 3730xl DNA analyser, Applied
Biosystems, Warrington, UK) identical to parental CAL 27 cells.
STR profiles were obtained contemporaneous to the in vivo
experiments (October 2013) and re-checked after completion
(August 2015).
All animal experiments were performed in accordance with
the local ethical review panel, the UK Home Office Animals
(Scientific Procedures) Act 1986, the United Kingdom National
Cancer Research Institute guidelines for the welfare of animals
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in cancer research (34), and the ARRIVE (Animal Research:
Reporting of In Vivo Experiments) guidelines (35). Female NCr-
Foxn1nu mice (7–8 weeks old, Charles River) were injected with
either 5 × 105 CALR or 5 × 106 CALS cells subcutaneously
in the right flank. Ten-fold fewer CALR cells were used to
compensate for the more rapid tumor growth rate of the
resulting xenografts in vivo (33). Animals were housed in specific
pathogen-free rooms in autoclaved, aseptic microisolator cages
with a maximum of four animals per cage. Food and water were
provided ad libitum. The mice were routinely monitored for the
appearance of palpable tumors and imaged at a tumor diameter
of∼0.8 to 1 cm.
MRI Data Acquisition
MRI was performed on a 7 T horizontal bore microimaging
system (Bruker, Ettlingen, Germany) using a 3 cm birdcage
volume coil. Anaesthesia was induced with an intraperitoneal
injection of fentanyl citrate (0.315mg ml−1) plus fluanisone
[10mg ml−1 (Hypnorm; Janssen Pharmaceutical Ltd., High
Wycombe, UK)], midazolam (5mg ml−1 [Hypnovel; Roche,
Welwyn Garden City, UK)], and sterile water (1:1:2). A lateral tail
vein was cannulated with a 27G butterfly catheter (Hospira, Royal
Leamington Spa, UK) for remote administration of contrast
media. Mice were positioned in the coil on a custom-built
platform to isolate the tumor, and with a nosepiece for gas
delivery, and their core temperature maintained at 37◦C with
warm air blown through the magnet bore.
Multiple contiguous 1mm thick axial T2-weighted images
were acquired for localization and subsequent quantitation of
the tumor volume. Magnetic field homogeneity was optimized
by shimming over the entire tumor volume using an automated
shimming routine (FASTmap).
For intrinsic susceptibility and oxygen-enhanced MRI,
multiple gradient recalled echo (MGRE) images [repetition time
(TR) = 200ms, 8 echo times (TE) ranging from 6 to 28ms,
4ms echo spacing, 8 averages, acquisition time (AQ) 2min 30 s],
and inversion recovery (IR) TrueFISP images (TE = 1.2ms,
TR = 2.4ms, 25 inversion times spaced 155ms apart, initial
inversion time of 109ms, total scan TR = 10 s, α = 60◦, 8
averages, AQ of 8min) were acquired from three contiguous
1mm slices across the center of the tumor over a 3 × 3 cm field
of view (FOV) and 128× 128 matrix whilst the host breathed air,
to enable quantitation of the transverse relaxation rate R2
∗ (s−1),
and the longitudinal relaxation rate R1 (s
−1), respectively. The
gas supply was then switched to 100% oxygen administered at 1 l
min−1 and, following a 5min transition time, identical MGRE
and IR-TrueFISP image sets were acquired (36).
Dynamic contrast enhanced (DCE-) MRI data were acquired
from a single 1mm thick, central axial slice across the tumor
using an inversion recovery (IR) true-FISP sequence with one
baseline scan (3 × 3 cm field of view, 128x96 matrix, TI = 25–
1451ms, 50 inversion times, TR = 2.4ms, TE = 1.2ms, 8
averages), and 60 dynamic scans (TI = 109–924ms, 8 inversion
times, TR = 2.4ms, TE = 1.2ms, scan TR = 10 s, 1 average,
60◦ flip angle, temporal resolution = 20 s) acquired for 3min
before and 17min after an i.v. injection of 0.1 mmol kg−1
of a clinically approved, low molecular weight contrast agent
gadolinium-DTPA (Gd-DTPA, Magnevist, Schering, Berlin,
Germany) (37). A single slice acquisition was used for the IR-
true-FISP sequence in order to minimize the temporal resolution
of the dynamic acquisition and thereby optimize the accuracy
of pharmacokinetic parameter estimates (38). The imaging slice
used herein was taken through the largest axial extent of the
tumor and assumed to be representative of the tumor as a whole.
Diffusion weighted (DW) images were acquired from the
same three 1mm thick axial slices as for intrinsic susceptibility
and oxygen-enhanced MRI using an echo-planar imaging (EPI)
sequence (3 × 3 cm FOV, 128 × 128 matrix, TR = 3,000ms, 5 b
values ranging from 40 to 700 s−1mm2, 4 averages).
MRI Data Analysis
Tumor volumes were determined using segmentation from
regions of interest (ROIs) drawn on T2-weighted images for
each tumor-containing slice. Functional MRI data were fitted
on a pixel-by-pixel basis using in-house software (Imageview,
developed in IDL, ITT Visual Information Systems, Boulder, CO,
USA). MGRE, IR-TrueFISP and DW images were fitted using
a Bayesian maximum a posteriori approach, allowing estimates
of the oxygen-induced change in R2
∗ (1R2
∗) and R1 (1R1),
and the median ADC to be calculated, respectively (39, 40).
For the IR-TrueFISP data, voxels with calculated T1 values
<200 or >3,000ms were excluded from the analysis. For DCE-
MRI analysis, IR true-FISP data were fitted using a similar
approach, utilizing the dual-relaxation sensitivity (T1 and T2) of
the pulse sequence and incorporating the Tofts and Kermode
pharmacokinetic model, providing estimates of Ktrans (37). In
addition, model-free analysis was used to derive the initial area
under the gadolinium uptake curve (IAUGC60, mM Gd min
−1)
from 0 to 60 s after injection of Gd-DTPA, and the ratio of
enhancing to total tumor volume (enhancing fraction; EF, %).
18F-Fluorodeoxyglucose (FDG) PET
Following overnight fasting, mice bearing CALR or CALS tumors
were continuously warmed using a heating pad prior to and
during the tracer uptake period. Both fasting andwarming reduce
normal/brown fat tissue radiotracer uptake, thereby enhancing
tumor contrast (41). Mice were intravenously administered with
6.2–6.5 MBq of 18F-FDG (Alliance Medical Radiopharmacy Ltd,
Sutton, UK) 30min after initiation of warming, and PET-CT
imaged 1 h later under isoflurane anesthesia using a trimodal
PET/SPECT/CT scanner (Carestream Health, Rochester, NY,
USA) for a duration of 600 s. A calibration phantom containing
∼0.5–1.5 MBq 18F-FDG was positioned in the middle of
the FOV and imaged simultaneously to ensure accurate
quantification of tumor tracer uptake. The total activity in
the FOV was <10 MBq, where acceptable linearity of the
PET scanner has previously been established (42). Each PET
scan was followed by a CT examination (45 kVp, 0.4mA,
250 projections) for attenuation correction and anatomical
localisation.
PET images were reconstructed with a maximum likelihood
expectation maximization algorithm using 12 iterations
and a voxel size of 0.5 mm3. Scatter, randoms and decay
correction were applied within the reconstruction with
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attenuation correction derived from the CT data. The CT
data was reconstructed with filtered back projection. The
PET/CT images were co-registered and analyzed using
PMOD (version 3.501, PMOD Technologies Ltd, Zurich,
Switzerland). Whole tumor ROIs were delineated using an
isocontour method based on 50% of the maximum tumor
uptake value, and the uptake of 18F-FDG quantified by
calculation of the mean percentage injected dose per gram
(%ID/g) using PMOD, corrected using the calibration phantom
data.
Histopathological Assessment of Tumor
Perfusion, Hypoxia, Glucose Transporter-1,
and Cellular Density
Mice bearing CALR or CALS tumors were administered the
hypoxia marker pimonidazole (60mg kg−1 i.p., Hypoxyprobe
Inc., Burlington, VT, USA) and the perfusion marker Hoechst
33342 (15mg kg−1 i.v., Sigma-Aldrich, Poole, UK), 45min and
1min, respectively, prior to necropsy. Tumors were rapidly
excised and bisected in the imaging plane at the position of
the central MRI slice, with half the tumor snap-frozen over
liquid nitrogen and the other half formalin-fixed and paraffin-
embedded (FFPE).
Fluorescence signals from reduced pimonidazole adducts
bound with mouse monoclonal FITC-conjugated antibodies
(Hypoxyprobe Inc.) and from Hoechst 33342 were detected
and quantified in whole tumor frozen sections (10µm) using
a motorized scanning stage (Prior Scientific Instruments,
Cambridge, UK) attached to a BX51 microscope (Olympus
Optical, London, UK), driven by image analysis software
(CellP, Soft Imaging System, Münster, Germany), as previously
described (37). Immunohistochemical (IHC) detection of glucose
transporter 1 (Glut-1) expression was performed on FFPE
sections (5µm), as previously described (43). In addition to
a composite whole tumor image, high magnification (x100)
images were acquired from ten randomly selected fields for
each tumor, from which the percentage of Glut-1 staining was
determined using color deconvolution in ImageJ (NIH, Bethesda,
MD, USA). Cellular density was assessed on haematoxylin and
eosin (H&E) stained FFPE sections by counting the number
of nuclei in four square ROIs from a total area of 0.01 mm2
per field (x200 magnification, six fields assessed per section)
(44).
Statistical Analysis
Statistical analysis of the MRI, PET and histopathological data
was performed with GraphPad Prism ver 6.07 (GraphPad
Software, La Jolla, CA, USA). Cohort sizes used for each
experiment are shown in each figure (N.B. each animal did not
necessarily undergo all the functional MRI scans). Results are
presented in the form of mean ± 1 s.e.m. Following application
of a Shapiro-Wilk normality test to confirm the Gaussian
distribution of the data, significance testing employed either
unpaired Student’s two-tailed t-test assuming equal variance or
the non-parametricMann-Whitney test as appropriate, with a 5%
level of significance.
RESULTS
HNSCC xenografts derived from EGFR TKI-resistant CALR cells
grew more rapidly than CALS tumors, as previously reported
(33). There was however no significant difference in the mean
tumor volumes (as determined by T2-weighted MRI) of the
CALR (533 ± 45 mm3) and CALS (506 ± 79 mm3) cohorts at
the time of imaging.
A hyperoxia-induced reduction in tumor R2
∗, resulting
from the flushing out of paramagnetic deoxyhaemoglobin with
diamagnetic oxyhaemoglobin, and altered tumor R1 arising
from more dissolved paramagnetic oxygen in blood, are being
actively investigated for the provision of imaging biomarkers
of hypoxia (36, 45). Parametric maps showing the spatial
distribution of oxygen-induced 1R2
∗ and 1R1 in a CAL
R and
a CALS tumor are shown in Figure 1A. Visually, hyperoxia
predominantly induced a heterogeneous reduction in R2
∗ in
both cohorts, which was greater in the CALS tumors. Overall,
a small, heterogeneous oxygen-induced increase in R1 was
the predominant response in both tumor types. No spatial
relationship between hyperoxia-induced 1R2
∗ and 1R1 was
apparent in either tumor type. Quantitatively, mean baseline
R2
∗ was significantly (p < 0.01) slower in the CALR (58 ± 2
s−1) than the CALS (70 ± 2 s−1) tumors. Oxygen-inhalation
resulted in an overall reduction in mean R2
∗ in both CALR (−4
± 1 s−1) and CALS (−11 ± 2 s−1) tumors, the response of the
CALS tumors being significantly (p < 0.01) greater than that
of the CALR xenografts (Figure 1B). There was no significant
difference in mean baseline R1 (0.49 ± 0.003 and 0.49 ± 0.007
s−1) and mean hyperoxia-induced 1R1 (0.05 ± 0.01 and 0.05
± 0.01 s−1) between the CALR and CALS tumors, respectively
(Figure 1C).
DCE-MRI measures contrast agent extravasation from the
blood plasma compartment to the extravascular extracellular
compartment, i.e., vascular leakage, typically expressed by the
volume transfer constant Ktrans (min−1). Increasing contrast
agent concentration in the extracellular leakage space is related
to both tumor perfusion and permeability (46). DCE-MRI
revealed that Gd-DTPA delivery was restricted to the periphery of
both CALR and CALS xenografts (Figure 2A). Pharmacokinetic
modeling of the DCE-MRI data revealed that Ktrans was
significantly (p < 0.01) lower in the CALR tumors (Figure 2B).
Model free analysis showed similarly significant lower IAUGC60
(0.0006± 0.0004 vs. 0.010± 0.005mMGd min−1, p< 0.01) and
EF (51± 6 vs. 82± 4%, p< 0.01) in the CALR xenografts.
DW-MRI exploits the random diffusion of water molecules
to measure differences in tissue cellularity, quantified through
the measurement of the apparent diffusion coefficient (ADC,
x106 mm2s−1) (47). Parametric ADC maps from both CALR
and CALS tumors were generally homogeneous, but with discrete
regions of markedly elevated water diffusion (Figure 2A). There
was no significant difference in mean ADC between the two
tumor types (Figure 2C).
Representative whole body PET-CT images acquired from
CALR and CALS tumor-bearing mice 1 h post injection of
18F-FDG are shown in Figure 3A. Greater uptake of 18F-
FDG was apparent across the CALR xenografts, resulting in
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FIGURE 1 | (A) Oxygen-induced 1R2* and 1R1 (both s
−1) parametric maps acquired from a CALR and a CALS HNSCC xenograft in vivo. (B,C) Summary of the
quantitative oxygen-enhanced MRI data, showing a significantly greater hyperoxia-induced 1R2* in the CAL
S relative to the CALR cohort. Data are the individual
oxygen-induced 1R2* and 1R1 measurements for each tumor, and the cohort mean ± 1 s.e.m., **p < 0.01, Student’s t-test.
FIGURE 2 | (A) Parametric maps of the transfer constant Ktrans (min−1) and the apparent diffusion coefficient, ADC (x10−6 mm2s−1), acquired from different CALR
and CALS HNSCC xenografts in vivo. (B,C) Summary of the quantitative DCE- and DWI MRI data, showing a significantly lower Ktrans in the CALR relative to the
CALS cohort. Data are the individual Ktrans and ADC measurements for each tumor, and the cohort mean ± 1 s.e.m., **p < 0.01, Mann-Whitney test.
a significantly (p < 0.05) higher %ID/g in the CALR tumors
compared to the CALS (Figure 3B). The relative difference
between the CALR and CALS xenograft tracer uptake was
quantified by normalizing the %ID/g results to the average value
found in the CALS cohort, and also revealed a significant 48%
(p< 0.05) higher relative uptake of 18F-FDG in the CALR tumors
(Figure 3C).
Composite fluorescence images of Hoechst 33342 and
pimonidazole adducts, and bright field images of Glut-1
expression, in whole sections from CALR and CALS tumors,
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FIGURE 3 | (A) Coronal whole body PET-CT images of mice bearing CALR and CALS HNSCC xenografts (arrowed) acquired 1 h post injection of 18F-FDG. The
images are shown on the same PET scale of 0–10% injected dose per gram (%ID/g). Marked uptake of 18F-FDG was also observed in the heart and bladder. (B,C)
A significantly higher relative uptake of 18F-FDG was determined in the CALR cohort compared to the CALS tumors. Data are the individual (B) %ID/g and (C)
normalized %ID/g for each tumor (relative to the average of the CALS cohort), and the cohort mean ± 1 s.e.m., *p < 0.05, Student’s t-test.
are shown in Figure 4A. Spatially, uptake of the perfusion
marker Hoechst 33342 was primarily associated with the
periphery of both tumor types, with hypoxic regions, as revealed
by pimonidazole adduct formation, more heterogeneously
distributed and predominantly located in the tumor core.
Abundant Glut-1 expression was apparent across the CALR
tumors, but more localized in the CALS xenografts. Quantitation
of the pathology showed significantly (p < 0.01) lower
perfusion, and significantly greater hypoxia (p < 0.01) and
Glut-1 expression (p < 0.05) in the CALR tumors relative
to the CALS cohort (Figure 4B). H&E staining revealed
abundant vesicle formation in both the CALR and CALS
tumors (Figure 4A). There was no significant difference in
cellular density between the two tumor types [CALR 45 ±
3 nuclei/0.01 mm2 (n = 7), CALS 49 ± 3 nuclei/0.01 mm2
(n= 5)].
DISCUSSION
Resistance is one of the major reasons for the failure of
targeted cancer drugs. The initial response and subsequent
relapse of HNSCC patients treated with EGFR TKIs is
well documented (13, 14). Methods that can accurately
predict which HNSCC patients will benefit from EGFR-
targeted therapies, and inform on response, would positively
impact on treatment planning in this patient population.
To this end, we evaluated MRI and PET-derived imaging
biomarkers in CALR and CALS HNSCC xenografts to
identify and characterize any phenotypic differences in vivo
associated with differential sensitivity to EGFR TKIs
(33).
Tumor hypoxia is a well-established cause of treatment
resistance, adversely affects the prognosis of HNSCC (21, 22),
and moderates the expression and activation of EGFR (26).
Both intrinsic susceptibility and oxygen-enhancedMRI are being
actively exploited for spatially mapping tumor hypoxia in vivo
(36, 45, 48–50). Oxygen inhalation induced a reduction in
R2
∗ of both CALR and CALS xenografts, a consequence of
a reduction in paramagnetic deoxyhaemoglobin in perfused
tumor blood vessels. The reduction in R2
∗ was significantly
smaller in the more aggressive CALR xenografts, consistent
with their having relatively more impaired haemodynamic
(functional) vasculature, and was confirmed histologically by
their significantly lower uptake of Hoechst 33342. Hyperoxia
increased R1 in both CAL
R and CALS xenografts to a similar
extent reported in other tumor models (36, 48, 49, 51, 52).
The low magnitude of this response suggests that these HNSCC
xenografts are largely refractory to hyperoxia-induced changes
in R1 and hence hypoxic (36, 48, 49). There was no relationship
between 1R2
∗ and 1R1 across the CAL
R and CALS tumors. As
expected, extensive hypoxia was histologically evident in both
CALR and CALS HNSCC xenografts, with significantly greater
pimonidazole adduct formation determined in the CALR tumors.
These data suggest that diminished hyperoxia-induced 1R2
∗
is associated with a more drug resistant phenotype, and re-
iterates the contribution of hypoxia in exacerbating resistance to
anti-EGFR therapies (26, 27).
The vascular patency and cellularity of CALR and CALS
xenografts was interrogated using DCE- and DW-MRI
respectively. The DCE-MRI biomarkers Ktrans, IAUGC60 and EF
all indicated significantly lower vascular permeability/perfusion
in the more hypoxic CALR xenografts, aligning with the lower
hyperoxia-induced 1R2
∗ response and reduced Hoechst 33342
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FIGURE 4 | (A) Composite fluorescence images of Hoechst 33342 uptake (blue, perfusion) and pimonidazole adduct formation (green, hypoxia), and bright field
images of Glut-1 expression (brown) and H&E staining, acquired from whole sections of representative CALR and CALS HNSCC xenografts. High magnification (x200)
images from H&E stained sections are also shown. (B) Summary of quantitative differences in perfused tumor vessels, hypoxia and Glut-1 expression in the CALR and
CALS tumors. Significantly lower Hoechst 33342 uptake, and significantly greater pimonidazole adduct formation and Glut-1 expression, was found in the CALR
tumors relative to the CALS cohort. Data are the individual measurements of Hoechst perfused area (%), pimonidazole adduct area (%) and Glut-1 expression (%) for
each tumor, and the cohort mean ± 1 s.e.m., **p < 0.01, *p < 0.05, Student’s t-test.
uptake seen in these tumors. The CALR phenotype is consistent
with clinical data showing that DCE-MRI estimates of perfusion
inversely correlate with pimonidazole adduct formation, and
that relatively high pre-treatment Ktrans is associated with good
response, in patients with HNSCC (53, 54). Whilst reduced
tumor perfusion/permeability measured by DCE-MRI may thus
be indicative of resistance to EGFR antagonists, it also reflects
diminished drug delivery and hence response. DW-MRI revealed
no significant difference in ADC between the CALR and CALS
xenografts, and H&E staining confirmed no overall difference in
cellular density. A recent study in HNSCC patients showed that
pre-treatment ADC was unable to distinguish between eventual
responders and non-responders to chemotherapy (55). Discrete
areas of elevated ADC were detectable in both CALR and CALS
xenografts, consistent with vesicle formation previously ascribed
to the CAL 27 model (56).
As with many aggressive tumors, HNSCCs exhibit high
rates of glycolysis to fulfill their energy requirements
(57, 58). 18F-FDG PET has been widely used to visualize
increased glycolysis in HNSCC in vivo (59). Accordingly,
18F-FDG uptake was clearly detected in both CALR and
CALS xenografts. Significantly greater uptake of 18F-FDG
was determined in the CALR tumors, and associated with
greater Glut-1 expression, as determined by IHC. Elevated
levels of lactate have also been reported in CALR, relative
to CALS, tumors (60). Together these data are consistent
with EGFR TKI-resistance being associated with a switch to
a more glycolytic metabolism in vivo. Tumor adaptation to
treatment with EGFR antagonists thus involves metabolic
reprogramming in HNSCC cells, enabling them to survive
in vivo despite an impaired functional vasculature and hypoxic
microenvironment.
Collectively, the data herein suggest that a multi-modal,
multiparametric MRI/PET imaging strategy, incorporating
intrinsic susceptibility and DCE-MRI with 18F-FDG PET,
may be useful in correctly identifying response/resistance to
TKIs in patients with HNSCC. Such integrated approaches
are already being used clinically to assess the degree and
spatial distribution of perfusion, hypoxia and metabolism in
HNSCC, and are being facilitated by new hybrid PET/MR
technology and associated data fusion (61–63). Incorporation
of quantitative R2
∗ measurements using intrinsic susceptibility
MRI into clinical scanning protocols is relatively straightforward,
and tumor R2
∗ is being actively investigated as an exploratory
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imaging biomarker of hypoxia in patients with HNSCC
(64).
Whilst this study has focused on characterizing the
radiological phenotype associated with resistance to
EGFR TKIs in xenografts, the same array of imaging
biomarkers may inform on tumor response in patients with
HNSCC. In support of this, several pre-clinical imaging
investigations have reported improved tumor oxygenation
(65), perfusion/permeability and water diffusivity (66, 67),
and reduced 18F-FDG uptake (68), following treatment with
gefitinib monotherapy or in combination with chemo/radiation
(69).
In summary, we have shown that xenografts established
from HNSCC cells resistant to EGFR TKIs are more hypoxic,
poorly perfused and more glycolytic than those sensitive to
EGFR inhibitors, and that these differences can be visualized
and quantified non-invasively in vivo using functional MRI and
PET imaging. These imaging techniques are either routinely
being used in the clinic or are under active development, so
adoption of a multi-modal, multiparametric imaging strategy
to assess HNSCC response and resistance to EGFR inhibition
would enhance expedient treatment selection and scheduling for
individual patients.
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